These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10422270)

  • 21. Treatment of experimental Cryptococcus neoformans infection in newborn rabbits by airway instillation of specific antibody and surfactant.
    Gross NT; Jarstrand C; Robertson B
    Lett Appl Microbiol; 2000 Sep; 31(3):218-22. PubMed ID: 10972732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.
    Alvarez M; Saylor C; Casadevall A
    Cell Microbiol; 2008 Aug; 10(8):1622-33. PubMed ID: 18384661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of anti-human neutrophil antibodies in vitro. Quantitative studies.
    Boxer LA; Stossel TP
    J Clin Invest; 1974 Jun; 53(6):1534-45. PubMed ID: 4208468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide.
    McGaw TG; Kozel TR
    Infect Immun; 1979 Jul; 25(1):262-7. PubMed ID: 383615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phagocytosis of viable Candida albicans by alveolar macrophages: lack of opsonin function of surfactant protein A.
    Rosseau S; Guenther A; Seeger W; Lohmeyer J
    J Infect Dis; 1997 Feb; 175(2):421-8. PubMed ID: 9203664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans.
    Cross CE; Collins HL; Bancroft GJ
    Immunology; 1997 Jun; 91(2):289-96. PubMed ID: 9227330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of surfactant on nitroblue tetrazolium reduction of polymorphonuclear leucocytes stimulated with type Ia group B streptococci.
    Herting E; Jarstrand C; Rasool O; Curstedt T; Håkansson S; Robertson B
    Acta Paediatr; 1995 Aug; 84(8):922-6. PubMed ID: 7488818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.
    Szymczak WA; Davis MJ; Lundy SK; Dufaud C; Olszewski M; Pirofski LA
    mBio; 2013 Jul; 4(4):. PubMed ID: 23820392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cryptococcus neoformans and Cryptococcus gattii clinical isolates from Thailand display diverse phenotypic interactions with macrophages.
    Hansakon A; Mutthakalin P; Ngamskulrungroj P; Chayakulkeeree M; Angkasekwinai P
    Virulence; 2019 Dec; 10(1):26-36. PubMed ID: 30520685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C1q enhances the phagocytosis of Cryptococcus neoformans blastospores by human monocytes.
    Bobak DA; Washburn RG; Frank MM
    J Immunol; 1988 Jul; 141(2):592-7. PubMed ID: 3290342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid peroxidation by alveolar macrophages challenged with Cryptococcus neoformans, Candida albicans or Aspergillus fumigatus.
    Gross NT; Hultenby K; Mengarelli S; Camner P; Jarstrand C
    Med Mycol; 2000 Dec; 38(6):443-9. PubMed ID: 11204882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo interaction between alveolar macrophages and Cryptococcus neoformans.
    Nessa K; Gross NT; Jarstrand C; Johansson A; Camner P
    Mycopathologia; 1997; 139(1):1-7. PubMed ID: 9511230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth inhibition of Cryptococcus neoformans by human alveolar macrophages.
    Weinberg PB; Becker S; Granger DL; Koren HS
    Am Rev Respir Dis; 1987 Nov; 136(5):1242-7. PubMed ID: 3314617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidative metabolic responses of rabbit pulmonary alveolar macrophages.
    Boxer LA; Ismail G; Allen JM; Baehner RL
    Blood; 1979 Mar; 53(3):486-91. PubMed ID: 760863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of phospholipid-containing surfactant from nickel exposed rabbits on pulmonary macrophages in vitro.
    Wiernik A; Jarstrand C; Johansson A
    Toxicology; 1981; 21(2):169-78. PubMed ID: 6895128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phagocytic activity and monocyte chemotactic protein expression by pulmonary macrophages in persistent pulmonary cryptococcosis.
    He W; Casadevall A; Lee SC; Goldman DL
    Infect Immun; 2003 Feb; 71(2):930-6. PubMed ID: 12540575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
    Kozel TR; Follette JL
    Infect Immun; 1981 Mar; 31(3):978-84. PubMed ID: 7014468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Killing of Cryptococcus neoformans by rat alveolar macrophages.
    Bolaños B; Mitchell TG
    J Med Vet Mycol; 1989; 27(4):219-28. PubMed ID: 2677299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surfactant protein D increases phagocytosis of hypocapsular Cryptococcus neoformans by murine macrophages and enhances fungal survival.
    Geunes-Boyer S; Oliver TN; Janbon G; Lodge JK; Heitman J; Perfect JR; Wright JR
    Infect Immun; 2009 Jul; 77(7):2783-94. PubMed ID: 19451250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans.
    Leopold Wager CM; Hole CR; Wozniak KL; Olszewski MA; Mueller M; Wormley FL
    Infect Immun; 2015 Dec; 83(12):4513-27. PubMed ID: 26351277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.